Compass Therapeutics Inc. has announced a new drug candidate, CTX-10726, a novel tetravalent PD-1 x VEGF-A bispecific antibody.

The dengue vaccine market is on track for robust growth, with increasing global awareness, governmental support, and ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications ...

To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can contact Valneva’s investor relations department at [email protected].

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla.